BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Astria Therapeutics Inc.

Headquarters: Boston, MA, United States of America
Year Founded: 2008
Status: Public
Industry Sector: HealthTechnology
CEO: Jill C. Milne, PhD
Number Of Employees: 59
Enterprise Value: $80,307,100
PE Ratio: -3.58
Exchange/Ticker 1: NASDAQ:ATXS
Exchange/Ticker 2: N/A
Latest Market Cap: $422,692,192

BioCentury | Feb 2, 2024
Finance

Public equity roundup: Alto, Fractyl price IPOs, Vaxcyte raises $750M

Plus: Kyverna lining up a listing next week, and PIPEs for Tectonic, Tyra and Arcus
BioCentury | Nov 7, 2023
Data Byte

October marks year’s third-biggest month for biotech follow-ons

The group’s median market cap performance was positive
BioCentury | Oct 14, 2023
Finance

Oct. 13 Quick Takes: Pfizer trims guidance, cutting costs by $3.5B due to COVID product sales

Plus: FDA approves Pfizer’s ulcerative colitis therapy from Arena deal and updates from Lilly, Novo, Harmony and more
BioCentury | Jul 18, 2023
Management Tracks

Ballinger at the helm at Lyndra

Plus: Bryan Stuart to lead Atavistik and updates from EnteroBiotix, PTC, CureVac, CytomX, ProKidney and more
BioCentury | Apr 19, 2023
Management Tracks

Astria promotes Matthews to CBO

Plus Engimmune hires Nieba as CEO and an update from Cardurion
BioCentury | Dec 16, 2022
Finance

Dec. 15 Quick Takes: Enlaza debuts with $61M, covalent targeting biologics platform

Plus: MinervaX taking strep vaccine to Phase II and updates from AbbVie, Prothena, Astria, Guardant and more
Items per page:
1 - 6 of 6
Help Center
Username
Request a Demo
Request Training
Ask a Question